Morphic Medical

Press Releases

Appointment of Director

Increase in the size of the Board from four to five directors and elected Dr. Praveen Tyle, Ph.D. to fill such vacancy and serve as a Class III director to serve until the 2020 Annual Meeting of Stockholders.

Read More »


How RESET Works

Maintenance of Efficacy After RESET

BBC News Item

DJBL for the treatment of type 2 diabetes and obesity: EASD 2022

Interested in joining the STEP-1 Trial?

Morphic is currently enrolling patients for its STEP-1 clinical study of RESET® in the United States. Learn more if you or someone you know are interested in participating in the study and would like to see if you qualify to join.

RESET® is limited by Federal (US) Law to investigational use only and is not for sale in any geography.